BlackRock Institutional Trust’s Travere Therapeutics TVTX Stock Holding History

BlackRock Institutional Trust’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$18.2M	Buy	961,157 +12,102	+1%	+$248K	﹤0.01%	2033
2016 Q3	$21.2M	Buy	949,055 +43,660	+5%	+$831K	﹤0.01%	1854
2016 Q2	$16.1M	Buy	905,395 +15,914	+2%	+$258K	﹤0.01%	1985
2016 Q1	$12.2M	Buy	889,481 +60,801	+7%	+$922K	﹤0.01%	2142
2015 Q4	$16M	Buy	828,680 +69,375	+9%	+$1.39M	﹤0.01%	2016
2015 Q3	$15.4M	Buy	759,305 +92,176	+14%	+$2.73M	﹤0.01%	2012
2015 Q2	$22.1M	Buy	667,129 +159,263	+31%	+$4.36M	﹤0.01%	1856
2015 Q1	$12.2M	Buy	507,866 +191,961	+61%	+$2.93M	﹤0.01%	2272
2014 Q4	$3.87M	Buy	315,905 +112,853	+56%	+$1.17M	﹤0.01%	2825
2014 Q3	$1.83M	Sell	203,052 -19,287	-9%	-$227K	﹤0.01%	3114
2014 Q2	$2.61M	Buy	222,339 +38,173	+21%	+$517K	﹤0.01%	3074
2014 Q1	$3.9M	Buy	+184,166	New	+$2.83M	﹤0.01%	2876

Other funds holding TVTX

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock Institutional Trust's TVTX Position: Q4 2016 in Review

BlackRock Institutional Trust increased its Travere Therapeutics (TVTX) stake by 1.3% in Q4 2016, buying an estimated $248K and bringing the position to 961,157 shares worth $18.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2033.

BlackRock Institutional Trust first reported a position in TVTX in Q1 2014 and has held it in 12 quarters since. The position peaked at $22.1M in Q2 2015. 121 funds tracked by Wall St. Rank hold TVTX as of Q4 2016.

BlackRock Institutional Trust held 961,157 shares of Travere Therapeutics worth $18.2M as of Q4 2016.
BlackRock Institutional Trust bought 12,102 Travere Therapeutics shares in Q4 2016, an estimated $248K.
Travere Therapeutics made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #2033 holding.
BlackRock Institutional Trust first reported a position in Travere Therapeutics in Q1 2014 and has held it in 12 quarters since.
BlackRock Institutional Trust's Travere Therapeutics position peaked at $22.1M in Q2 2015.
121 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.